View Older Stories View More Recent Stories

Nov 1, 2022 07:00AM Numinus Re-Launches "Psychedelic Therapy Frontiers" Podcast with additional hosts and topics
Oct 31, 2022 07:00AM Numinus to Participate in Wonderland: Miami on November 3-5, 2022
Oct 28, 2022 07:00AM Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
Oct 7, 2022 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022
Oct 5, 2022 07:30AM Numinus Develops Mushroom Tea for Use in Psychedelic Research
Sep 29, 2022 04:01PM Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022
Sep 22, 2022 07:00AM Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives
Sep 19, 2022 07:00AM Numinus Now Offers Ketamine-Assisted Therapy in Toronto
Sep 13, 2022 07:00AM Numinus provides update on acquisition integration and announces new client financing options
Aug 31, 2022 07:30AM Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Aug 30, 2022 07:30AM Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board
Jul 14, 2022 04:01PM Numinus Wellness Inc. Reports Q3 2022 Results
Jul 6, 2022 07:30AM Numinus to Host Q3 2022 Results Conference Call on July 14, 2022
Jun 27, 2022 07:00AM Numinus Unveils New Logo and Brand Identity
Jun 23, 2022 07:00AM Numinus Pilots Mental Health Program for Corporate Clients in Utah
Jun 22, 2022 07:00AM Numinus Applies for International Patent Filing of Psychedelics Production Process
Jun 21, 2022 04:05PM Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
Jun 10, 2022 07:30PM Numinus completes acquisition of Novamind and announces executive appointments
Jun 8, 2022 04:05PM Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind
May 31, 2022 07:00AM Numinus announces ISS recommends shareholders vote in favor of the share issuance to acquire Novamind
May 16, 2022 07:30AM Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
May 11, 2022 07:30AM Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
May 10, 2022 07:30AM Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement
May 9, 2022 07:30AM Numinus to Participate in Upcoming Research & Industry Conferences
Apr 29, 2022 08:30AM Numinus Announces the Music as Medicine Event Series
Apr 14, 2022 04:00PM Numinus Wellness Inc. Reports Q2 2022 Results
Apr 12, 2022 07:00AM Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Apr 7, 2022 07:30AM Numinus to Participate in Upcoming Investor Conferences in April 2022
Apr 1, 2022 07:30AM Numinus to Host Q2 2022 Results Conference Call on April 14, 2022
Mar 30, 2022 07:30AM Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Mar 15, 2022 07:30AM Numinus to Participate in Maxim's 2022 Virtual Growth Conference on March 28-30, 2022
Mar 14, 2022 07:30AM Numinus Expands Natural Psychedelic Research with New Biosecurity License
Mar 9, 2022 07:30AM Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
Feb 28, 2022 05:39PM Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
Feb 10, 2022 07:30AM Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022
Feb 1, 2022 07:30AM Numinus Appoints New Bioscience Advisors to Advance IP Development
Jan 27, 2022 08:30AM Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
Jan 26, 2022 05:15PM Numinus Wellness Inc. Graduates to the OTCQX Best Market
Jan 25, 2022 08:00AM Numinus to Participate in Citi's Psychedelic Drug Call Series on February 2, 2022
Jan 20, 2022 04:01PM Numinus Wellness Inc. Reports Q1 2022 Results
Jan 19, 2022 08:00AM Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Jan 14, 2022 08:00AM Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
Jan 13, 2022 07:32PM Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders
Jan 7, 2022 05:04PM Numinus Announces Q1 2022 Results Conference Call Update
Jan 5, 2022 08:00AM Numinus to Host Q1 2022 Results Conference Call on January 13, 2022
Dec 22, 2021 05:00PM Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
Dec 14, 2021 06:00PM Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021
Dec 9, 2021 05:02PM Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Nov 30, 2021 08:30AM Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
Nov 29, 2021 05:30AM Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans
View More Recent Stories View Older Stories